Crinetics Pharmaceuticals, Inc.
CRNX
$34.47
-$0.57-1.63%
Weiss Ratings | CRNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Very Weak | |||
Risk Index | Weak | |||
Risk Grade | D | |||
Reward Grade | E | |||
Rating Factors | CRNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Index | -- | |||
Growth Index | Weak | |||
Efficiency Index | Very Weak | |||
Solvency Index | Excellent | |||
Total Return Index | Fair | |||
Volatility Index | Weak | |||
Beta / Standard Deviation | CRNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Beta | 1.16 | |||
Price History | CRNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | 1.06% | |||
30-Day Total Return | -14.47% | |||
60-Day Total Return | -36.90% | |||
90-Day Total Return | -39.20% | |||
Year to Date Total Return | -33.13% | |||
1-Year Total Return | -11.46% | |||
2-Year Total Return | 100.52% | |||
3-Year Total Return | 80.66% | |||
5-Year Total Return | 199.22% | |||
52-Week High % Change | -44.87% | |||
52-Week Low % Change | 8.26% | |||
Price | CRNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
52-Week High Price | $62.53 | |||
52-Week Low Price | $31.84 | |||
52-Week Low Price (Date) | Feb 25, 2025 | |||
52-Week High Price (Date) | Nov 14, 2024 | |||
Valuation | CRNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Market Cap | 3.21B | |||
Enterprise Value | 1.91B | |||
Price/Earnings (TTM) | -- | |||
Earnings Per Share (TTM) | -3.71 | |||
Earnings Per Share Growth | 0.23% | |||
Price/Earnings To Growth | -- | |||
Price/Sales (TTM) | 3,050.44 | |||
Price/Book (Q) | 2.42 | |||
Enterprise Value/Revenue (TTM) | 1,833.53 | |||
Price | $34.47 | |||
Enterprise Value/EBITDA (TTM) | -5.67 | |||
Enterprise Value/EBIT | -5.62 | |||
Market Cap Category | Mid Cap | |||
Dividends and Shares | CRNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Shares Outstanding | 91.49M | |||
Dividend Yield | -- | |||
Div. Per Share (Most Recent) | -- | |||
Dividend Per Share (TTM) | -- | |||
Payout Ratio (TTM) | -- | |||
Dividend Per Share (Most Recent) | -- | |||
Company Info | CRNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Phone Number | 858 450 6464 | |||
Address | 6055 Lusk Boulevard San Diego, CA 92121 | |||
Website | www.crinetics.com | |||
Country | United States | |||
Year Founded | 2008 | |||
Profitability | CRNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Operating Margin (TTM) | -32,613.47% | |||
Profit Margin | -28,720.69% | |||
Management Effectiveness | CRNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Return on Assets | -20.46% | |||
Return on Equity | -- | |||
Income Statement | CRNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Revenue (TTM) | 1.04M | |||
Total Revenue (TTM) | 1.04M | |||
Revenue Per Share | $0.01 | |||
Gross Profit (TTM) | -239.12M | |||
EBITDA (TTM) | -336.07M | |||
EBIT (TTM) | -338.85M | |||
Net Income (TTM) | -298.41M | |||
Net Income Avl. to Common (TTM) | -298.41M | |||
Total Revenue Growth (Q YOY) | -- | |||
Earnings Growth (Q YOY) | -34.11% | |||
EPS Diluted (TTM) | -3.71 | |||
EPS Diluted Growth (Q YOY) | 1.58% | |||
Balance Sheet | CRNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash and Short-Term Inv. (Q) | 1.35B | |||
Cash Per Share (Q) | $14.80 | |||
Total Current Assets (Q) | 1.38B | |||
Total Preferred Equity (Q) | -- | |||
Total Equity (Q) | 1.32B | |||
Current Ratio (Q) | 23.045 | |||
Book Value Per Share (Q) | $14.26 | |||
Total Assets (Q) | 1.43B | |||
Total Current Liabilities (Q) | 59.68M | |||
Total Debt (Q) | 51.72M | |||
Total Liabilities (Q) | 109.79M | |||
Total Common Equity (Q) | 1.32B | |||
Cash Flow | CRNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash from Investing (TTM) | -574.82M | |||
Cash from Financing (TTM) | 1.01B | |||
Net Change in Cash (TTM) | 209.65M | |||
Levered Free Cash Flow (TTM) | -136.41M | |||
Cash from Operations (TTM) | -225.97M | |||